The “Infodemic” of COVID‐19

Some in the medical publishing world have observed an "infodemic" occurring alongside the pandemic. One might define an infodemic as a contagious disease infecting our information culture. As the Editors of A&R, tasked with conducting, reviewing, reporting, and translating science to the rheumatic disease community, we agree with this diagnosis. Herein, we reflect on how the pandemic has impacted A&R, the medical publishing world, and how we may best engage our community to navigate current challenges.

[1]  B. Medhi,et al.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.

[2]  L. Henderson,et al.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1 , 2020, Arthritis & rheumatology.

[3]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[4]  Amit N. Patel,et al.  Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.

[5]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[6]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[7]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[8]  D. Raoult,et al.  Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France , 2020, Travel Medicine and Infectious Disease.

[9]  Stefano Volpi,et al.  On the Alert for Cytokine Storm: Immunopathology in COVID‐19 , 2020, Arthritis & rheumatology.

[10]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[11]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.